RSS Feeds
Immune Thrombocytopenia Associated with Efalizumab Therapy for Psoriasis
- Theodore E. Warkentin, MD; and
- Paul Kwon, MD
- From Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada and Genentech, South San Francisco, CA 94080.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Efalizumab is a recombinant humanized anti-CD11a monoclonal IgG1 antibody. Efalizumab recognizes the α-subunit of leukocyte function-associated antigen type 1, thereby blocking interaction between the antigen and intercellular adhesion molecules and …
